As a preamble, I'm not an MD, or a licensed healthcare professional.
One way to improve that might be to give the networks permission to access the other network's information. I've had to do it a couple of times, and then professionals on all sides can see everyone's prescriptions, and perhaps more importantly, their internal software has a chance to flag potential counter indications and side effects.
As a general comment: clinical trials to approve any given drug are generally set up so the single drug is given to one group of patients and the current "recommended" drug is given to the other. For some trials, the two groups may be switched half way through. Unless disease or disorder requires multiple drugs as a starting point, most drugs aren't tested with other drugs. That means that drug interactions between two or more drugs are almost entirely worked out in patients after approvals, with patients who have a variety of disease(s) states, and backgrounds. So if drug #1 plus 2,3,4 causes something unwanted, often all four drugs will get tagged with a contraindication, even though some other combination of those drugs with a fifth, or all but one, might work.
I think that multiple drug therapy is very complicated, but when the doctor decides that the patient needs it, that's not my call.
All the best, Peter